Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
NCT: NCT04770337 · COMPLETED
Brief Summary
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse events will be collected and evaluated.
Frequently Asked Questions
What is Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy?
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy is a clinical trial registered under NCT04770337. Current status: COMPLETED.
What is the status of NCT04770337?
The current status of NCT04770337 (Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy) is: COMPLETED.
When did Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy start?
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy started on 2021-10-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.